Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9742 · 5 trials · 4 indications
Adverse events, vital signs, electrocardiograms, telemetry, physical exams, and clinical laboratory assessments will be assessed prior to, during, and after treatment
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Single dose of 750mg of intravenous AZD9742 in healthy elderly volunteers |
| 2 | PLACEBO_COMPARATOR | Sterile 5% dextrose solution |
| AZD9742 IV Infusion | EXPERIMENTAL | Active |
| Placebo to AZD9742 IV Infusion | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD9742 | DRUG | Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL |
| Placebo | DRUG | Sterile 5% dextrose solution |
| Diltiazem | DRUG | Orally, daily beginning on Day 4 for 14 consecutive days |
| ketoconazole | DRUG | 200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered |
| Placebo to match AZD9742 | DRUG | Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) |
Inclusion Criteria: * Male and female volunteers at age of 65 years or older with suitable veins for cannulation or repeated venipuncture, in good health (based on medical history and physical examination and clinical laboratory tests) as judged by the investigator. * Female volunteers must be post...
AZD9742 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in Phase 1 clinical trials involving healthy volunteers, including elderly and Japanese subjects, to assess safety, tolerability, and pharmacokinetics. The specific therapeutic indication for AZD9742 has not been disclosed.
AZD9742 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical trials conducted for this asset.
AZD9742 is in Phase 1 clinical development. All five of its registered trials are Phase 1 studies, and all have been completed. The drug remains investigational and has not been approved by the FDA for any indication.
AZD9742 has been evaluated in five completed Phase 1 trials, including NCT01154621, NCT01124760, NCT01114152, and NCT01064388. These studies enrolled a total of 159 participants and examined safety, tolerability, and pharmacokinetics in healthy volunteers, including elderly and Japanese subjects.
AZD9742 does not have a disclosed therapeutic indication. Its clinical trials were conducted in healthy volunteers to assess safety, tolerability, and pharmacokinetics rather than to treat a specific disease. It remains an investigational agent without an approved use.